28279-12-1

Basic information

• Product Name: 9-methyl-2,8,10-triazabicyclo[4.4.0]deca-2,4,8,11-tetraen-7-one
• Synonyms: 9-methyl-2,8,10-triazabicyclo[4.4.0]deca-2,4,8,11-tetraen-7-one;2-methylpyrido[2,3-d]pyrimidin-4-ol;2-methylpyrido[2,3-d]pyrimidin-4(3H)-one(SALTDATA: FREE);3,4-Dihydro-2-methylpyrido[2,3-d]pyrimidin-4-one;2-methyl-1H-pyrido[3,2-e]pyrimidin-4-one;2-Methyl-4-hydroxy-pyrido(2,3-d)pyrimidine;Pyrido(2,3-d)pyrimidin-4-ol, 2-methyl-;2-methylpyrido[2,3-d]pyrimidin-4(1H)-one
• CAS NO: 28279-12-1
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16
• Mol File: 28279-12-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 262-264℃ (methanol )
• Boiling Point: 340.8°Cat760mmHg
• Flash Point: 159.9°C
• Appearance: /
• Density: 1.4g/cm³
• Vapor Pressure: 8.39E-05mmHg at 25°C
• Refractive Index: 1.695
• CAS DataBase Reference: 9-methyl-2,8,10-triazabicyclo[4.4.0]deca-2,4,8,11-tetraen-7-one(CAS DataBase Reference)
• NIST Chemistry Reference: 9-methyl-2,8,10-triazabicyclo[4.4.0]deca-2,4,8,11-tetraen-7-one(28279-12-1)
• EPA Substance Registry System: 9-methyl-2,8,10-triazabicyclo[4.4.0]deca-2,4,8,11-tetraen-7-one(28279-12-1)

Safety Data

• Hazardous Substances Data: 28279-12-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H7N3O/c1-5-10-7-6(8(12)11-5)3-2-4-9-7/h2-4H,1H3,(H,9,10,11,12)

Upstream product

• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 75-36-5 acetyl chloride 
• 3809-93-6 2-Methyl-4H-pyrido<2,3-d><3,1>oxazin-4-one 
• 14667-47-1 methyl 2-aminonicotinate 
• 13438-65-8 2-aminopyridine-3-carboxamide 
• 78-39-7 Triethyl orthoacetate 
• 119899-26-2 2-fluoronicotinic acid chloride 
• 143-37-3 acetamidine 
• 1445-45-0 Trimethyl orthoacetate 
• 60-35-5 acetamide 

Downstream Products

• 161874-92-6 2-methyl-4-chloropyrido<2,3-d>pyrimidine 
• 199114-24-4 4-[2-[4-methyl-2-propyl-6-oxo-1,6-dihydropyrimidin-1-yl]ethoxy]benzaldehyde 

Relevant articles and documents

Chemical Space Exploration around Thieno[3,2- d]pyrimidin-4(3 H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors

Clostridium difficile infection (CDI) is the leading cause of healthcare-associated infection in the United States. Therefore, development of novel treatments for CDI is a high priority. Toward this goal, we began in vitro screening of a structurally diverse in-house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-4(3H)-one (2) with moderate potency (MIC = 312/156 μM). Optimization of 2 gave lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one) with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s > 606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid. Further optimization of 6a at C2-, N3-, C4-, and C7-positions resulted in a library of >50 compounds with MICs ranging from 3 to 800 μM against clinical isolates of C. difficile. Compound 8f (MIC = 3/6 μM) was identified as a promising lead for further optimization.

Substituted fused pyrimidinone and dihydro-pyrimidone

The use of substituted fused pyrimidinones and dihydropyrimidinones of the formula (I) or salts thereof where the radicals of the formula (I) are each as defined in the description, for enhancing stress tolerance in plants to abiotic stress, and for invigorating plant growth and/or for increasing plant yield.

PROCESS FOR PRODUCING PYRIMIDIN-4-ONE COMPOUND

A pyrimidin-4-one compound can be prepared in a high yield by reacting an aminoarylcarboxylic acid compound with an organic acid compound in the presence of a nitrogen atom-containing compound under relatively simple and moderate reaction conditions.